Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE.

Werth BJ, Barber KE, Tran KN, Nonejuie P, Sakoulas G, Pogliano J, Rybak MJ.

J Antimicrob Chemother. 2015 Feb;70(2):489-93. doi: 10.1093/jac/dku386. Epub 2014 Oct 9.

PMID:
25304643
2.

Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes.

Barber KE, Werth BJ, Ireland CE, Stone NE, Nonejuie P, Sakoulas G, Pogliano J, Rybak MJ.

J Antimicrob Chemother. 2014 Nov;69(11):3006-10. doi: 10.1093/jac/dku236. Epub 2014 Jul 1.

PMID:
24990867
3.

β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium.

Smith JR, Barber KE, Raut A, Aboutaleb M, Sakoulas G, Rybak MJ.

J Antimicrob Chemother. 2015;70(6):1738-43. doi: 10.1093/jac/dkv007. Epub 2015 Feb 1.

4.

Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model.

Hall Snyder A, Werth BJ, Barber KE, Sakoulas G, Rybak MJ.

J Antimicrob Chemother. 2014 Aug;69(8):2148-54. doi: 10.1093/jac/dku113. Epub 2014 Apr 28.

PMID:
24777900
5.

Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium.

Sakoulas G, Bayer AS, Pogliano J, Tsuji BT, Yang SJ, Mishra NN, Nizet V, Yeaman MR, Moise PA.

Antimicrob Agents Chemother. 2012 Feb;56(2):838-44. doi: 10.1128/AAC.05551-11. Epub 2011 Nov 28.

6.

Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.

Smith JR, Yim J, Raut A, Rybak MJ.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2352-8. doi: 10.1128/AAC.03006-15. Print 2016 Apr.

7.

β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models.

Smith JR, Barber KE, Raut A, Rybak MJ.

Antimicrob Agents Chemother. 2015 May;59(5):2842-8. doi: 10.1128/AAC.00053-15. Epub 2015 Mar 9.

8.

Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates.

Arias CA, Singh KV, Panesso D, Murray BE.

Antimicrob Agents Chemother. 2007 Jun;51(6):2043-7. Epub 2007 Apr 16.

9.

Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci.

Rand KH, Houck H.

J Antimicrob Chemother. 2004 Mar;53(3):530-2. Epub 2004 Feb 12.

PMID:
14963062
10.

In vitro activity of daptomycin in combination with β-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci.

Hindler JA, Wong-Beringer A, Charlton CL, Miller SA, Kelesidis T, Carvalho M, Sakoulas G, Nonejuie P, Pogliano J, Nizet V, Humphries R.

Antimicrob Agents Chemother. 2015 Jul;59(7):4279-88. doi: 10.1128/AAC.05077-14. Epub 2015 May 11.

11.

Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model.

Arias CA, Singh KV, Panesso D, Murray BE.

J Antimicrob Chemother. 2007 Sep;60(3):594-8. Epub 2007 Jul 2.

PMID:
17606481
12.

Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium.

Sakoulas G, Rose W, Nonejuie P, Olson J, Pogliano J, Humphries R, Nizet V.

Antimicrob Agents Chemother. 2014;58(3):1494-500. doi: 10.1128/AAC.02274-13. Epub 2013 Dec 23.

13.

Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.

Farrell DJ, Flamm RK, Sader HS, Jones RN.

Int J Antimicrob Agents. 2014 Apr;43(4):323-7. doi: 10.1016/j.ijantimicag.2013.11.005. Epub 2013 Dec 11.

PMID:
24411474
14.

Ceftaroline Plus Ampicillin Against Gram-Positive Organisms: Results from E-Test Synergy Assays.

D'Arezzo S, Mazzarelli A, Venditti C, Nisii C, Petrosillo N, De Giuli C, Vulcano A, Paglia MG, Bordi E, Di Caro A, Taglietti F.

Microb Drug Resist. 2017 Jun;23(4):507-515. doi: 10.1089/mdr.2016.0030. Epub 2016 Aug 15.

PMID:
27526275
15.
16.

Early in vitro development of daptomycin non-susceptibility in high-level aminoglycoside-resistant Enterococcus faecalis predicts the efficacy of the combination of high-dose daptomycin plus ampicillin in an in vivo model of experimental endocarditis.

Pericàs JM, García-de-la-Mària C, Brunet M, Armero Y, García-González J, Casals G, Almela M, Quintana E, Falces C, Ninot S, Fuster D, Llopis J, Marco F, Moreno A, Miró JM; Hospital Clinic Endocarditis Study Group.

J Antimicrob Chemother. 2017 Jun 1;72(6):1714-1722. doi: 10.1093/jac/dkx016.

PMID:
28204495
17.

Daptomycin-reversible rifampicin resistance in vancomycin-resistant Enterococcus faecium.

Rand KH, Houck HJ, Silverman JA.

J Antimicrob Chemother. 2007 May;59(5):1017-20. Epub 2007 Mar 16.

PMID:
17369277
18.

[In vitro activity of daptomycin against VRE and MRSA strains].

Aktaş G, Derbentli S.

Mikrobiyol Bul. 2014 Jan;48(1):123-8. Turkish.

19.

Simple test of synergy between ampicillin and vancomycin for resistant strains of Enterococcus faecium.

Green M, Barbadora K, Wadowsky RM.

J Clin Microbiol. 1994 Nov;32(11):2837-9.

20.

Supplemental Content

Support Center